Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network

Nature Genetics

Volumn 47, Issue 11, 2015, Pages 1334-1340

  Caye, Aurélie ^a,b,c   Strullu, Marion ^a,c   Guidez, Fabien ^a   Cassinat, Bruno ^a,d   Gazal, Steven ^e,f   Fenneteau, Odile ^c   Lainey, Elodie ^a,b,c   Nouri, Kazem ^g   Nakhaei Rad, Saeideh ^g   Dvorsky, Radovan ^g   Lachenaud, Julie ^a,c   Pereira, Sabrina ^c   Vivent, Jocelyne ^a,c   Verger, Emmanuelle ^a,d   Vidaud, Dominique ^b,h   Galambrun, Claire ⁱ   Picard, Capucine ^b,j,k   Petit, Arnaud ^l   Contet, Audrey ^m   Poirée, Marilyne ⁿ   Sirvent, Nicolas ^o   Méchinaud, Françoise ^p   Adjaoud, Dalila ^q   Paillard, Catherine ^r   Nelken, Brigitte ^s   Reguerre, Yves ^t   Bertrand, Yves ^u   Häussinger, Dieter ^v   Dalle, Jean Hugues ^b,c   Ahmadian, Mohammad Reza ^g   Baruchel, André ^b,c   Chomienne, Christine ^a,b,d   Cavé, Hélène ^a,b,c   more..

^a Hôpital Saint Louis   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITÉ PARIS DIDEROT   (France)

^g Department of Orthopedic Surgery   (Germany)

^h Medical Faculty of the Heinrich Heine University ^*  (France)

ⁱ TIMONE HOSPITAL   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k INSERM   (France)

^l ARMAND TROUSSEAU HOSPITAL   (France)

^m CHU NANCY BRABOIS   (France)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^o MONTPELLIER UNIVERSITY HOSPITAL   (France)

^p NANTES UNIVERSITY HOSPITAL   (France)

^q GRENOBLE UNIVERSITY HOSPITAL   (France)

^r HÔPITAL DE HAUTEPIERRE   (France)

^s LILLE UNIVERSITY HOSPITAL   (France)

^t Centre Hospitalier Departemental Felix Guyon   (France)

^u Institut d'Hémato Oncologie Pédiatrique IHOP   (France)

^v HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; HISTONE H3; LYSINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCOMB REPRESSIVE COMPLEX 2; RAC2 PROTEIN; RAS PROTEIN; HISTONE; PROTEIN SUBUNIT; TRANSCRIPTOME;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER TRANSPLANTATION; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE LOSS; GENE TARGETING; GENETIC ASSOCIATION; GENETIC DISORDER; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS TYPE 1; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN METHYLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; WHOLE EXOME SEQUENCING; ACETYLATION; ACUTE DISEASE; CONFOCAL MICROSCOPY; COPY NUMBER VARIATION; DISEASE COURSE; DNA SEQUENCE; GENE REGULATORY NETWORK; GENETICS; INFANT; METABOLISM; METHYLATION; MUTATION; MYELOID LEUKEMIA; PRESCHOOL CHILD; PROCEDURES; PROTEIN SUBUNIT; SURVIVAL ANALYSIS;

ACETYLATION; ACUTE DISEASE; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE REGULATORY NETWORKS; HISTONES; HUMANS; INFANT; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; METHYLATION; MICROSCOPY, CONFOCAL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN SUBUNITS; RAS PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84945484387     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3420     Document Type: Article

References (61)

1. Chang, T.Y., Dvorak, C.C., & Loh, M.L. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 124, 2487-2497 (2014).
2. Niemeyer, C.M., et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 89, 3534-3543 (1997).
3. Locatelli, F., & Niemeyer, C.M. How I treat juvenile myelomonocytic leukemia. Blood 125, 1083-1090 (2015).
4. Niemeyer, C.M. RAS diseases in children. Haematologica 99, 1653-1662 (2014).
5. Shlien, A., et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257-262 (2015).
6. Sakaguchi, H., et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45, 937-941 (2013).
7. Strullu, M., et al. Juvenile myelomonocytic leukaemia and Noonan syndrome. J. Med. Genet. 51, 689-697 (2014).
8. Niemeyer, C.M., et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat. Genet. 42, 794-800 (2010).
9. Pérez, B., et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J. Med. Genet. 47, 686-691 (2010).
10. Makishima, H., et al. Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942-946 (2013).
11. Brown, K.M., et al. Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc. Natl. Acad. Sci. USA 110, E1533-E1542 (2013).
12. Flex, E., et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum. Mol. Genet. 23, 4315-4327 (2014).
13. Shang, X., et al. R-Ras and Rac GTPase cross-Dalk regulates hematopoietic progenitor cell migration, homing, and mobilization. J. Biol. Chem. 286, 24068-24078 (2011).
14. Kawazu, M., et al. Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc. Natl. Acad. Sci. USA 110, 3029-3034 (2013).
15. Emanuel, P.D. Hallway gossip between Ras and PI3K pathways. Blood 123, 2751-2753 (2014).
16. Goodwin, C.B., et al. PI3K p110d uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood 123, 2838-2842 (2014).
17. Worzfeld, T., et al. Genetic dissection of plexin signaling in vivo. Proc. Natl. Acad. Sci. USA 111, 2194-2199 (2014).
18. Innocenti, M., et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 160, 17-23 (2003).
19. Offenhäuser, N., et al. The eps8 family of proteins links growth factor stimulation to actin reorganization generating functional redundancy in the Ras/Rac pathway. Mol. Biol. Cell 15, 91-98 (2004).
20. Cutts, B.A., et al. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood 114, 3629-3632 (2009).
21. Xu, J., et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 3, 993-1001 (2013).
22. Wang, J., et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose-And cell type-dependent manner. Blood 118, 368-379 (2011).
23. Khan, S.N., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27, 1301-1309 (2013).
24. Son, J., Shen, S.S., Margueron, R., & Reinberg, D. Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev. 27, 2663-2677 (2013).
25. Kinkel, S.A., et al. Jarid2 regulates hematopoietic stem cell function by acting with Polycomb repressive complex 2. Blood 125, 1890-1900 (2015).
26. Ciferri, C., et al. Molecular architecture of human Polycomb repressive complex 2. eLife 1, e00005 (2012).
27. Puda, A., et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am. J. Hematol. 87, 245-250 (2012).
28. Zhang, Y., et al. Corepressor protein CDYL functions as a molecular bridge between Polycomb repressor complex 2 and repressive chromatin mark trimethylated histone lysine 27. J. Biol. Chem. 286, 42414-42425 (2011).
29. Abdel-Wahab, O., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180-193 (2012).
30. Abdel-Wahab, O., & Levine, R.L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 121, 3563-3572 (2013).
31. Kim, E., et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617-630 (2015).
32. Huether, R., et al. The landscape of somatic mutations in epigenetic regulators across 1, 000 paediatric cancer genomes. Nat. Commun. 5, 3630 (2014).
33. Yang, F. PRC2 dysfunction through multiple mechanisms in myeloid malignancies. Epigenomics 5, 481 (2013).
34. Pasini, D., et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 38, 4958-4969 (2010).
35. Leiserson, M.D., et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106-114 (2015).
36. Lee, W., et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1227-1232 (2014).
37. Zhang, M., et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1170-1172 (2014).
38. De Raedt, T., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247-251 (2014).
39. Jaiswal, S., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014).
40. Genovese, G., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014).
41. Jacobs, K.B., et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat. Genet. 44, 651-658 (2012).
42. Laurie, C.C., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat. Genet. 44, 642-650 (2012).
43. Locatelli, F., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105, 410-419 (2005).
44. Takagi, M., et al. Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML. Leukemia 27, 1926-1928 (2013).
45. Matsuda, K., et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109, 5477-5480 (2007).
46. Matsuda, K., et al. Acquisition of loss of the wild-Dype NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica 92, 1576-1578 (2007).
47. Kato, M., et al. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy. J. Pediatr. 162, 1285-1288 (2013).
48. Kalra, R., Paderanga, D.C., Olson, K., & Shannon, K.M. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84, 3435-3439 (1994).
49. Chan, R.J., Cooper, T., Kratz, C.P., Weiss, B., & Loh, M.L. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk. Res. 33, 355-362 (2009).
50. Pérez, B., et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br. J. Haematol. 151, 460-468 (2010).
51. Ahmadian, M.R., Stege, P., Scheffzek, K., & Wittinghofer, A. Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat. Struct. Biol. 4, 686-689 (1997).
52. Hemsath, L., & Ahmadian, M.R. Fluorescence approaches for monitoring interactions of Rho GTPases with nucleotides, regulators, and effectors. Methods 37, 173-182 (2005).
53. Eberth, A., & Ahmadian, M.R. In vitro GEF and GAP assays. Curr. Protoc. Cell Biol. Chapter 14, Unit 14.9 (2009).
54. Jaiswal, M., Dubey, B.N., Koessmeier, K.T., Gremer, L., & Ahmadian, M.R. Biochemical assays to characterize Rho GTPases. Methods Mol. Biol. 827, 37-58 (2012).
55. Eberth, A., et al. A BAR domain-mediated autoinhibitory mechanism for RhoGAPs of the GRAF family. Biochem. J. 417, 371-377 (2009).
56. Jaiswal, M., Dubey, B.N., Koessmeier, K.T., Gremer, L., & Ahmadian, M.R. Biochemical assays to characterize Rho GTPases. Methods Mol. Biol. 827, 37-58 (2012).
57. Gremer, L., et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum. Mutat. 32, 33-43 (2011).
58. Nakhaei-Rad, S., et al. The function of embryonic stem cell-expressed RAS (E-RAS), a unique RAS family member, correlates with its additional motifs and its structural properties. J. Biol. Chem. 290, 15892-15903 (2015).
59. Worthylake, D.K., Rossman, K.L., & Sondek, J. Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1. Nature 408, 682-688 (2000).
60. Morreale, A., et al. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat. Struct. Mol. Biol. 7, 384-388 (2000).
61. Nassar, N., Hoffman, G.R., Manor, D., Clardy, J.C., & Cerione, R.A. Structures of Cdc42 bound to the active and catalytically compromised forms of Cdc42GAP. Nat. Struct. Biol. 5, 1047-1052 (1998).